Sanofi

Clinical Study Results Medicines, including Rare Diseases

Important

Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country. In the event that the product is described as no longer a Sanofi product, reasons could include that the product was transferred to another company.

This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

Filter by:

And

1248 result(s) found
Generic NameTrade NameCondition(s)Study CodeStudy NameAccess to Study / ProtocolAccess to Results
LIXISENATIDE
Lyxumia
Diabetes Mellitus, Type 2
SFY13476NANCT01960179Summary
LIXISENATIDE
Lyxumia
Diabetes Mellitus, Type 2
TDR14311NAEudraCT: 2015-005789-42Tabulated Results
LPA1 RECEPTOR ANTAGONIST
Not marketed
Systemic Sclerosis
ACT12339NAEudraCT: 2012-001369-34Tabulated Results
LUNSEKIMIG
Not marketed
Asthma
PDY16622NANCT05366764Publication
LYSINE ACETYLSALICYLATE
Aspegic
Tonsillitis
L_8620ALPHIN 1Summary
MAGNESIUM LACTATE DIHYDATE + PYRIDOXINE HYDROCHLORIDE
MagnaB6
Low Magnesium Levels
MGLACC07810MB6 SUPERIORITYEudraCT: 2015-003749-24Tabulated Results
MAYTANSINOID LOADED ANTI-CD19 MAB
Not marketed
Lymphoma
ARD10248STARLYTEEudraCT: 2011-003657-26Publication's Reference Posted
MAYTANSINOID LOADED ANTI-CD19 MAB
Not marketed
Lymphoma
EFC11603MYRALLNCT01440179Publication's Reference Posted
MAYTANSINOID LOADED ANTI-CD19 MAB
Not marketed
Lymphoma
TCD12333NAEudraCT: 2011-002865-39Tabulated Results
MET INHIBITOR
Not marketed
Lung Cancer
ACT14205NAEudraCT: 2014-005696-93Tabulated Results

References:

* These study results were previously posted on GenzymeClinicalResearch.com
** This link replaces the same summary that was previously posted